Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05633654
Title Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)
Acronym ASCENT-05
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.